- Home
- LOMA vs SANA Comparison
LOMA vs SANA Comparison
Compare LOMA & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LOMA | SANA |
|---|---|---|
| Founded | 1926 | 2018 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LOMA | SANA |
|---|---|---|
| Price | $12.06 | $4.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $15.00 | $7.83 |
| AVG Volume (30 Days) | 289.0K | ★ 2.5M |
| Earning Date | 03-05-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $464,306,268.00 | N/A |
| Revenue This Year | $22.92 | N/A |
| Revenue Next Year | $25.84 | N/A |
| P/E Ratio | $197.77 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.04 | $1.26 |
| 52 Week High | $14.17 | $6.55 |
Technical Indicators
Market Signals| Indicator | LOMA | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 48.65 | 57.11 |
| Support Level | $11.25 | $4.36 |
| Resistance Level | $12.50 | $5.20 |
| Average True Range (ATR) | 0.54 | 0.34 |
| MACD | -0.07 | 0.04 |
| Stochastic Oscillator | 43.10 | 69.13 |
Price Performance
Historical ComparisonAbout LOMA Loma Negra Compania Industrial Argentina Sociedad Anonima ADS
Loma Negra Cia Industria Argentina SA is a cement producer in Argentina. The company operates in five segments: Cement, masonry cement, and lime; Concrete; Rail services; Aggregates; and Others. The majority of its revenue derives from Cement, masonry cement, and lime segments.
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.